Experienced in Li-Fraumeni Syndrome

Dr. Elizabeth Lokich

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Affinity Physicians Llc.
455 Toll Gate Rd, 
Warwick, RI 
Accepting New Patients
Experienced in Li-Fraumeni Syndrome
Affinity Physicians Llc.
455 Toll Gate Rd, 
Warwick, RI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Lokich is a Gynecologic Oncologist and an Oncologist in Warwick, Rhode Island. Dr. Lokich is rated as an Experienced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy. Dr. Lokich is currently accepting new patients.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in RI
Hospital Affiliations
Women & Infants Hospital Of Rhode Island
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

AFFINITY PHYSICIANS LLC.
455 Toll Gate Rd, Warwick, RI 02886

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

16 Total Publications

The effect of intrawound vancomycin powder on surgical site infection in inguinal lymph node dissection: a randomized controlled trial pilot study.
The effect of intrawound vancomycin powder on surgical site infection in inguinal lymph node dissection: a randomized controlled trial pilot study.
Journal: Gynecologic oncology reports
Published: April 21, 2025
Similar Doctors
Distinguished in Li-Fraumeni Syndrome
Dr. Judy E. Garber
Hematology Oncology | Oncology | Hematology
Distinguished in Li-Fraumeni Syndrome
Dr. Judy E. Garber
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

101 Columbian St, 
South Weymouth, MA 
 (42.2 miles away)
781-340-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Judy Garber is a Hematologist Oncology specialist and an Oncologist in South Weymouth, Massachusetts. Dr. Garber is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, Li-Fraumeni Syndrome, and Tieche-Jadassohn Nevus. Dr. Garber is currently accepting new patients.

Nadine M. Tung
Distinguished in Li-Fraumeni Syndrome
Dr. Nadine M. Tung
Hematology Oncology | Oncology
Distinguished in Li-Fraumeni Syndrome
Dr. Nadine M. Tung
Hematology Oncology | Oncology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (47.8 miles away)
617-754-8612
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nadine Tung is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Tung is rated as an Elite provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Breast Cancer, Ovarian Cancer, HER-2 Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Tung is currently accepting new patients.

Advanced in Li-Fraumeni Syndrome
Dr. Karyn J. Hansen
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Li-Fraumeni Syndrome
Dr. Karyn J. Hansen
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Trinity Health Of New England Provider Network Organization Inc

428 Hartford Tpke, 
Vernon, CT 
 (52.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Karyn Hansen is a Gynecologic Oncologist and an Oncologist in Vernon, Connecticut. Dr. Hansen is rated as an Advanced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, and Li-Fraumeni Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lokich's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile